このエントリーをはてなブックマークに追加
ID 61280
フルテキストURL
fulltext.pdf 2.02 MB
著者
Sakatani, Akio Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Igawa, akuro Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences,
Okatani, Takeshi Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Fujihara, Megumu Department of Pathology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Asaoku, Hideki Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Sato, Yasuharu Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID Kaken ID researchmap
Yoshino, Tadashi Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Kaken ID publons researchmap
抄録
Classic Hodgkin lymphoma (CHL) is a lymphoid neoplasia characterized by the presence of large tumor cells, referred to as Hodgkin and Reed-Sternberg (HRS) cells, originating from B-cells in an inflammatory background. As the clinical significance of B-cell markers has yet to be fully elucidated, this study aimed to clarify the clinicopathological significance of CD79a in 55 patients with CHL. They were immunohistochemically divided into two groups, comprising of 20 CD79a-positive and 35 CD79a-negative patients. There was no significant correlation between CD79a and CD20 expression (rs = 0.125, P = 0.362). CD79a-positive patients were significantly older at onset (P = 0.011). There was no significant correlation between CD79a-positivity and clinical stage (P = 0.203), mediastinal involvement (P = 0.399), extranodal involvement (P = 0.749), or laboratory findings, including serum levels of lactate dehydrogenase (P = 1) and soluble interleukin-2 receptor (P = 0.251). There were significant differences in overall survival (OS) (P = 0.005) and progression-free survival (PFS) (P = 0.007) between CD79a-positive and CD79a-negative patients (5-year OS: 64.6% and 90.5%; 5-year PFS: 44.0% and 76.6%, respectively). Five patients in whom the majority (> 80%) of HRS cells expressed CD79a consisted of 4 males and 1 female aged between 52 and 81 years; 4 of them were in a limited clinical stage. We concluded that CD79a-positive CHL may have unique clinicopathological features.
キーワード
classic Hodgkin lymphoma
CD79a
prognosis
immunohistochemistry
発行日
2020
出版物タイトル
Journal of Clinical and Experimental Hematopathology
60巻
3号
出版者
The Japanese Society for Lymphoreticular Tissue Research
開始ページ
78
終了ページ
86
ISSN
1346-4280
NCID
AA11556796
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
© 2020 by The Japanese Society for Lymphoreticular Tissue Research
論文のバージョン
publisher
PubMed ID
NAID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.3960/jslrt.20010
ライセンス
https://creativecommons.org/licenses/by-nc-sa/4.0/